诊疗指南

采用抗血栓形成药物对缺血性脑血管疾病患者进行围手术期管理

Periprocedural Management of Antithrombotic Medications in Patients with Ischemic Cerebrovascular Disease
来源:MDC 2013-06-05 14:01 发表评论

Objective: To assess evidence regarding periprocedural management of antithrombotic drugs in patients with ischemic cerebrovascular disease. The complete guideline on which this summary is based is available as an online data supplement to this article.

Methods: Systematic literature review with practice recommendations.

Results and recommendations: Clinicians managing antithrombotic medications periprocedurally must weigh bleeding risks from drug continuation against thromboembolic risks from discontinuation. Stroke patients undergoing dental procedures should routinely continue aspirin (Level A). Stroke patients undergoing invasive ocular anesthesia, cataract surgery, dermatologic procedures, transrectal ultrasound–guided prostate biopsy, spinal/epidural procedures, and carpal tunnel surgery should probably continue aspirin (Level B). Some stroke patients undergoing vitreoretinal surgery, EMG, transbronchial lung biopsy, colonoscopic polypectomy, upper endoscopy and biopsy/sphincterotomy, and abdominal ultrasound–guided biopsies should possibly continue aspirin (Level C). Stroke patients requiring warfarin should routinely continue it when undergoing dental procedures (Level A) and probably continue it for dermatologic procedures (Level B). Some patients undergoing EMG, prostate procedures, inguinal herniorrhaphy, and endothermal ablation of the great saphenous vein should possibly continue warfarin (Level C). Whereas neurologists should counsel that warfarin probably does not increase clinically important bleeding with ocular anesthesia (Level B), other ophthalmologic studies lack the statistical precision to make recommendations (Level U). Neurologists should counsel that warfarin might increase bleeding with colonoscopic polypectomy (Level C). There is insufficient evidence to support or refute periprocedural heparin bridging therapy to reduce thromboembolic events in chronically anticoagulated patients (Level U). Neurologists should counsel that bridging therapy is probably associated with increased bleeding risks as compared with warfarin cessation (Level B). The risk difference as compared with continuing warfarin is unknown (Level U).

    
学科代码:神经病学 神经外科学   关键词:抗血栓形成药物 缺血性脑血管疾病 围手术期管理 ,指南 爱思唯尔医学网, Elseviermed
文章来源:MDC
MDC介绍: MD Consult 是爱思唯尔公司于1997年推出的新一代智慧型医学咨询平台,包含50多部著名医学参考书,88种全文医学期刊和北美临床系列杂志,10000篇患者手册,1000份诊疗指南,以及持续更新的药品信息,医学新闻,并支持PDA功能,为医生解答医学及科研问题,让医生紧贴第一手医学发展信息,并迅速以其优质的内容和方便时效的服务赢得了很高的声誉。 请点击申请试用并填写联系信息,我们将每月为前100位申请者发送带有用户名、密码及网页链接的电子邮件,请您注意查收!感谢您的参与及使用!请点击此处登录MD Consult。。马上访问MDC网站:http://www.mdconsult.com/
顶一下(4
您可能感兴趣的指南
发表评论网友评论(0)
发表评论
登录后方可发表评论,点击此处登录